At least 100 million doses of the Pfizer / BioNTech vaccine coronavirus will buy Chinese pharmaceutical company FosunPharma to give to mainland China residents of the year, although Chinese companies are producing their own vaccines against covid-19.
The Pfizer / BioNTech vaccine has already been approved for use in several countries, including Britain and the USA, where it has already started to be administered.
Chinese laboratories are working on experimental coronavirus vaccines, which have already begun to be given in the country to the most vulnerable populations, but without having yet received the approval of the authorities for widespread use, as reported by AMPE.
In a statement to the Hong Kong Stock Exchange, Shanghai-based FosunPharma said BioNTech would offer “at least 100 million doses of its coronavirus vaccine in mainland China in 2021.”
FosunPharma will pay 250 million euros in advance for the delivery of the first 50 million installments. The two companies will share the profits from vaccine sales in mainland China, Macau and Hong Kong, with two-thirds going to Fosun and one-third to BioNTech.
In China, where the coronavirus pandemic first appeared in late 2019, has given great weight to growth vaccine, with President Xi Jinping promising that it would be a “global, public good.”
China develops four coronavirus vaccines, which are in the final phase of testing. Chinese laboratories have conducted tests in various countries, including Brazil, the United Arab Emirates and Turkey. In Peru, Sinopharm vaccine trials have been suspended after a volunteer developed neurological problems.
Abu Dhabi has already started vaccinating its residents against covid-19 with the Sinopharm vaccine.
However, on Monday the Brazilian regulator (Anvisa) announced that China had used “opaque” criteria to authorize the emergency use of another Chinese vaccine, Sinovac’s CoronoVac